Bristol-Myers adds new U.S. manufacturing facility for viral vector production

Bristol Myers Squibb (BMY) announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.-based manufacturing facility and its operations in Libertyville, Illinois, following the company’s execution of an agreement with Novartis (NVS). The facility and its operations have capabilities to produce viral vector for both of Bristol Myers Squibb’s CAR T cell therapies. This development advances the company’s long-term ambitions in cell therapy. The new U.S. facility is planned to transition to Bristol Myers Squibb over the course of 2023, subject to the fulfillment of applicable closing conditions.